Ab Cellera submits NASDAQ IPO application to raise $3.57...

Recently, AbCellera announced that it had filed for a NASDAQ IPO to raise $357 million.
May, the company completed a $105 million round of B financing.
A. Cellera is an AI-driven antibody discovery company.
company's core technology is a high-flung microflow platform that uses miniaturized laboratory methods to screen antibodies from millions of immune cells from any species, including directly from human patients.
the company's unique antibody visualization and exploration software, Celium™, to quickly search and analyze the natural immune system in depth, providing high-quality antibody candidates.
addition, the platform can be customized according to the type of disease and application objectives, in the screening of alternative antibodies to further structural optimization and source optimization.
In collaboration with other companies, AbCellera applies its technology to the treatment of a wide range of diseases, including cancer, neurodegenerative changes, pain, fibrosis and metabolic disorders, to produce unsolveed treatment options.
The technology's effectiveness is fully demonstrated in the context of the COVID-19 pandemic: LY-CoV555, a candidate antibody therapy developed in combination with Eli Lilly and Company, is one of the first new coronavirus and antibody therapies to enter clinical trials.
Ab Cellera was also named the "50 Most Innovative Companies in the World" this year by Fierce Biotech 2020 Fierce 15 and Fast Company, a leading U.S. business media company.
addition, AbCellera has made two acquisitions this year to expand its pipeline: in August, it acquired OrthoMab, Dualogics' dual-specific antibody platform, and in November, it bought Trianni for $90 million, jointly developing the next generation of genetically modified mice to provide an all-human source of antibodies for the discovery of therapeutic antibodies.
long research and development cycle, low success rate and high research and development costs have been difficulties for new drug research and development.
artificial intelligence, with its powerful discovery relationship and computing power, has the potential to overcome these problems, and has therefore received the attention of capital.
year, a number of AI-plus new drug companies have completed different rounds of financing, including multiple financings of more than $100 million.
we also look forward to the rapid emergence of more AI-based drugs, with the help of capital, for the benefit of more patients.
: . . . Ab Cellera, tapped by Lilly for its COVID-19 antibody therapy, sets IPO terms with $5B valuation. Retrieved December 8, 2020, from Ab Cellera Inc. prospecto. Retrieved December 8, 2020, from。